Vital's ELAD misses in liver failure Phase III

Vital Therapies Inc. (NASDAQ:VTL) plummeted $13.33 (75%) to $4.35 in early after-hours trading on Friday after its ELAD system missed the primary and secondary endpoints in the Phase III VTI-208 trial to treat alcohol-induced liver decompensation (AILD).

Patients in the treatment vs. control groups showed no difference in the primary endpoint of overall survival (OS) through at least day 91 (HR=1.027; p=0.90) nor on the secondary endpoint of proportion of survivors at day 28 (p=0.45) and day 91 (p=0.74). ...